dr. I Gede Subawa, MKes

President Director of PT Askes Indonesia

Phrarmaceutical Sector Meeting on 8 November 2012 Nikko Bali Resort Spa, Nusa Dua, Bali

SUPPLY SIDE OF HEALTH INSURANCE SYSTEM IN INDONESIA

www.ptaskes.com

www.ptaskes.com

Overview Of Indonesia

• Total population : 237,641,326 (2010 National Census) • Gross national income per capita (PPP international $):

3,600 • Life expectancy at birth m/f (years): 66/71 • Probability of dying under five (per 1 000 live births) : 34

(2007) • Probability of dying between 15 and 60 years m/f (per 1 000

population) : 234/143 • Total expenditure on health per capita (Intl $, 2009) : 99 • Total expenditure on health as % of GDP (2009) : 2.4

Source; WHO (2012)

ECONOMIC GROWTH OF INDONESIA

0%

1%

2%

3%

4%

5%

6%

7%

8%

9%

10%

2007 2008 2009 2010 2011 2012 2013 2014

Indonesia Emerging/Developing Economies ASEAN

Indonesia real GDP grow faster than ASEAN and emerging/developing economies … % GDP growth (real) 2007 - 2014

www.ptaskes.com

PER CAPITA INCOME GROWTH

0%

20%

40%

60%

80%

2008 2010 2012 2014

% Gr

owth

ASEAN

Emerging/Developing

Economies

…& per capita income is also expected to grow faster % Per Capita income growth 2007 - 2014

www.ptaskes.com

INDONESIAN POPULATION GROWTH

116,9 123,8116,6 123,7233,5 247,6

050100150200250300

2010 2015

Po

pu

la

tio

n (M

) Female Population (m)

Male Population (M)

Source: BPS (Central Statistics Bureau)

INDONESIAN POPULATION GROWTH Growth at 6% to 2015

Increasing life expectancy will create demand for chronic therapies

The elderly population increase in the next 5 years

0 to 1010 to 1920 to 2930 to 3940 to 4950 to 5960 to 69

70+2010 2015

www.ptaskes.com

DISTRIBUTION OF POPULATION

42,0% 48,3% 54,2% 59,5%

58,0% 51,7% 45,8% 40,5%

0%

20%

40%

60%

80%

100%

2000 2005 2010 2015

Po

pu

latio

n S

plit b

y

Urb

an

/Ru

ra

l (%

)

Rural

Urban

Indonesia population increasingly moving to urban area

2000 2010 2005 2015

www.ptaskes.com

7

HEALTHCARE SPENDING

Source: 1Worldbank report, WHO Global Atlas, Datamonitor

0,0%

0,5%

1,0%

1,5%

2,0%

2,5%

3,0%

3,5%

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

% GDP spent on healthcare growing 2.4% of GDP (USD 44 per capita)

7 www.ptaskes.com

Source: 1Worldbank report, WHO Global Atlas, Datamonitor

…% spend is low compared to peer countries % GDP Spent on Healthcare, comparative

0

2

4

6

8

Vie

tnam

Wor

ld A

vg

Mal

aysi

a

Phi

lippi

nes

Thai

land

Sin

gapo

re

Indo

nesi

a

Mya

nmar

HEALTHCARE SPENDING

www.ptaskes.com

www.ptaskes.com

Indonesia Healthcare Transformation Universal Healthcare Coverage in 2014

• Indonesia Minister of Health has already set a target to start covering all people’s health costs as early as 2014.

• Law No. 40/2004 on National Social Security System (SJSN)

• Law No. 36/2011 on Social Security Implementation – BPJS I (Health Insurance Carrier)

• ASKES +JAMKESMAS merge

• 5 Committees are now working to set the Insurance System

www.ptaskes.com

Healthcare Transformation System Sistem Jaminan Sosial Nasional – Universal Health Coverage 2014

PT JAMSOSTEK

PT ASKES

PT TASPEN

PT ASABRI

Dewan Jaminan Sosial Nasional (National Social Security Council)

BPJS 1 BPJS 2

PT

JAM

SOST

EK

PT

ASK

ES

PT

TASP

EN

PT

ASA

BR

I

MOH JAMKESMAS

MO

H J

AM

KES

MA

S

Less fortunate/Poor

Employee – Health, Accident & Pension fund

Civil servants & Military Retirement

Pension for civil servants

Active Military Health Non-Health

Current

www.ptaskes.com

2014

HISTORY PT ASKES (PERSERO)

1968: BPDPK

1984: PERUM HUSADA BHAKTI

1992: PT ASKES (PERSERO)

2014: Health Insurance Carrier ( BPJS)

Reimbursement

Managed care

Managed care

1968: Minister of Health: as an embryo of Universal Coverage

www.ptaskes.com

ROAD MAP TO UHC

Preparation

Preparation

FORMAL SECTOR (ASKES, JAMKESMAS, JAMSOSTEK,

MILITARY/POLICE, BUMN/BUMD, SWASTA

FORMAL SECTOR BUMN/BUMD, SELF WORKER,

POOR, DISTRICT

INFORMAL SECTOR SELF WORKER, PBI

UC

2013

2014

2015

2019 ?

2012

2016

BPJS-1 (Health UHC Organization)

BPJS-2 (Pension Organization)

www.ptaskes.com

Integration between quality and cost control

• Gatekeeper concept Primary care • Quality Assurances Credentialing & Recredentialing • Comprehensive health care benefits • Emphasizes on promotion and prevention • Referral system • Drugs Formularium DPHO • Prospective payment system • Utilization review • Medical Advisory Board

MANAGED CARE

14 www.ptaskes.com

Supply Side - UHC Health Insurance Specialist

Supply Side

15 www.ptaskes.com

Legal Aspect

UU 40/2004

• 23 (1)

(1) Benefit Delivery by BPJS Provider.

• 24 (1) (2) (3)

(1) Payment Negotiation BPJS vs Provider Association

(2) BPJS obligated to pay the provider at the latest 15 day

(3) BPJS develop a healthcare system, quality control, provider payment mechanism (efficiency and effectiveness)

• UU 24/2011: 11 (d) (e)

(d) Provider payment Regulator;

(e) Provider contract BPJS;

16 www.ptaskes.com

Health Insurance Specialist

17

PROVIDER MANAGEMENT

BPJS (proposed)

1.Provider Mapping

• Primary, Secondary, Tertiary

• Provider with catastrophic care

• Pharm, Optical, Laboratory

2. Cre/Recredentialing

• All Provider

3. Payment Nego & Provider Contract

• BPJS nego to Provider Assosciation

• BPJS contract to provider

4. Updating Provider List

• Referensi Provider On Line (public)

5. Performance of Provider Evaluation

• Utilization Review, customer satisfaction

• Medical Audit, Cost Effectiveness, Comprehensiveness

PT Askes (Persero)

1.Provider Mapping

• Primary provider

• Provider with catastrophic care

2. Cre/Recredentialing

• All Provider

3. Payment Nego & Provider Contract

• Nego & Contract to Provider

4. Updating Provider List

• Referensi Provider On Line (internal)

5. Performance of Provider Evaluation

• Utilization Review, customer satisfaction

ASKES VS BPJS

Health Insurance Specialist

ROAD MAP HEALTH FACILITIES MANAGEMENT

Qt I

• Policy

Synchronizat

ion

• Finalization

of guideline

Qt II

• Socialization

of health

facilities

Qt III

• Health

Facilities

Selection

Qt IV

• Negotiation

• Contract

Semester I

• Perfomance

Evalualuation

of Health

Facilities

• Implementati

on of

Regional

Partnerships

Year 2013 Year 2014 Alt.1:

Qt I

• Policy

Synchronizat

ion

• Finalization

of guideline

Qt II

• Socialization

of health

facilities

Semester II

• Negotiation

• Contract with Health

Facilities:

Askes, Jamsostek,

TNI/POLRI, Jamkesmas, )

Semester I

• Perfomance

Evalualuation

of Health

Facilities

• Implementati

on of

Regional

Partnerships

Alt.2: Year 2013 Year 2014

Health Insurance Specialist

Take Precedence Accredited

If not accredited: • Administrative Criteria

• Having a license from ministry of Health and local Government. • Having a business license as a health Facilities. • AMDAL

• Facilities Criteria • Having facilities in accordance with the applicable regulation • Having medical and administrative personnel according to

regulations and the needs of the participants. • Strategic location.

• Quality Criteria • Having a quality accredited certification or other quality

certification.

Health Insurance Specialist Health Facilities Criteria

ASKES HEALTH CARE PROVIDERS 2011 Regional I

Regional II

Regional III

Regional IV

Regional V

Regional VI

Regional VII

Regional VIII

Regional IX

Regional X

Regional XI

Regional XII

• 8.774 Community Health Centers

• 3.753 Family Physicians/24 hours Clinic

• 270 Laboratories, 231 Indonesian Red Cross

• 952 Hospitals (506 Government hospitals; 109 TNI/POLRI hospitals; 263 private hospitals; 74 special hospitals)

• 162 providers for hemodialysis

• 1.184 pharmacies dan 756 optical

Regional XI

DPHO (List of Drugs Items and Prices) As a drugs in Universal Health Coverage

www.ptaskes.com

• Indonesia has an enormous number of drugs that are available on the market :

15,498 items (Ind. FDA 2012)

208 farmacies

• a problem of Askes to select an appropriate and qualified drugs for its members

• ASKES must ensure that the drugs are selected according to evidence based criteria (EBM)

• the problem of distribution is an issue to be overcome, and which creates drug price disparity among the islands

• A widely range of drug’s price

WHY SELECTION?

www.ptaskes.com

WITH THOSE CIRCUMSTANCES ASKES

DESIGN A DRUGS POLICY FOR ITS MEMBERS

EFFECTIVE, SAFE AND EFFICIENT List of Drug Items and Prices

(DPHO, Since 1987)

www.ptaskes.com

Annual update of the DPHO.

www.ptaskes.com

- Expert Team consist of : Pharmacologyst, Specialist, Health Ministry, and The National Agency of Food and Drug Control

- Hospital Recomendation consists of National Essential Medicines List, Generic and Branded Generic that had not been included in the recent DPHO

DPHO COMPOSEMENT PROCESS

DPHO & QUALITY OF SERVICES

• DPHO Board of Experts review the drug list by considering EBM and analyzing cost effectiveness.

• DPHO Board of Experts conducts a series of intensive discussions every week for 6 months every year.

• DPHO is composed based on the result of Board of experts recommendation to ensure all medical needs are accommodated for outpatient care (primary and specialist), and inpatient care.

• DPHO Board of Experts also recommends and specifies particular indications for certain drugs (restrictions), in order to ensure:

Prescribing is in accordance with treatment guidelines. Improving patient compliance with chronic disease medicines. Decreasing overuse of antibiotics. Decreasing overuse of injections. Increasing use of generic medicines.

www.ptaskes.com

PRICING THE DRUGS

• The price negotiation is conducting after the quality of drugs is assured by certifying they fully meet of the following: Product Information, including meta analysis. Indonesia Food and Drugs Agency Register. Certificate of Analysis (COA). Good Manufacturing Practice (GMP) or Indonesian

Certification of Good Manufacturing Practice. • Price negotiation with pharmaceutical industries only at national

level. • By offering a large, fixed, captive market to the pharmaceutical

industry, ASKES could obtain a significantly efficient price of up to 60% off the regular market price.

• The same price is implemented around the country

www.ptaskes.com

INDEPENDENCY OF DRUG FORMULARY

www.ptaskes.com

1. Selection process efektive dan efficient

• efficacy & safety aspect by Experts Team

• Price and distribution by ASKES Team

2. Label use defined DPHO Experts Team

indications, restriction and maximum prescribe

3. Price based on negotiation between ASKES- Manufacturers including special arrangement

4. Askes Drug Formulary (DPHO) is designed for one year :

• The same policy and price around the country

• Evaluate and re-formulate every year

Members: – Health care services availability – Health care services quality

Health Care Providers: – More Choices and affailability – Assurance of Drugs Quality and Availability – Quality of Services Evidence-based practice

Manufacturers : – Captive Market, – Less Marketing Cost – Economies of Scales

Government : – Efficiency of Health Care Spending

DPHO BENEFIT FOR STAKEHOLDER

www.ptaskes.com

OPTIMIZING DPHO IMPLEMENTATION

• Prescriber in government and private providers (primary, secondary, tertiary) should follow the drugs in DPHO for treating any ASKES patients.

• Communicating with ASKES members about the advantages of DPHO.

• Provide a scientific seminar or medicine workshop for prescribers at least four times each year at every ASKES branch office.

• Special analyses from the Medical Advisory Board (MAB) at every ASKES branch. The Medical Advisory Board recommends the medical judges and provides a second opinion in term of evidence based medicine drugs prescription.

• Review and evaluation of drug utilization, also prescribing drugs outside of DPHO.

www.ptaskes.com

www.ptaskes.com

•Number of Drugs in DPHO, Years 2007 – 2012

•Number of Therapy Class in DPHO vs DOEN, Years 2007 – 2012

DPHO CONTENT

EVALUATION OF DPHO

www.ptaskes.com

Members trustworthiness of using DPHO medicine increase every year

Outpatient Utilization

EVALUATION OF DPHO

www.ptaskes.com

Members trustworthiness of using DPHO medicine increase every year

Inpatient Utilization

EVALUATION OF DPHO

DPHO CONTENT

www.ptaskes.com

Antineoplastic and Paliatif Treatment - Cytotoxic

Indication:

For

gastrointestinal

cancer

Indication:

For metastases

breast cancer

with Positive 3

(+++) HER2 of

Positive FISH

Indication:

For Limfoma

Non Hodgkins

(LNH) Malignum

with Positive

CD20

Sample description of the Indication Guide for prescribing

Challenges • Wide variety of kind and price available in the

market potential to overuse, misuse

Inefficient

• Over prescription and irrational prescription

• Provider Compliances moral hazards

• Commitment from Distributor/Manufacturer

• Effectiveness of the drug’s prescription control

www.ptaskes.com

www.ptaskes.com Divisi Jaminan Pelayanan Kesehatan